Ipsen Publishes Liquidity Contract Assessment as of December 31, 2025
The biopharmaceutical group Ipsen has released the data for the liquidity contract entrusted to Natixis Oddo BHF for the second half of 2025. As of December 31, 2025, the liquidity account held 30,064 shares and 2.13 million euros.
Liquidity Account Details
According to the press release issued on January 6, 2026, the liquidity account dedicated to Ipsen contained a total of 30,064 shares and 2,126,437.66 euros in cash as of December 31, 2025. These figures should be compared with the initial situation at the time the contract was set up, which included 12,751 shares and 3,137,934.80 euros. The evolution of these amounts reflects the activity of the provider Natixis Oddo BHF in its role of regulating the price and liquidity of Ipsen's shares on the market. The biopharmaceutical group, listed on Euronext Paris under the ticker IPN, thus uses this contractual arrangement to ensure smoother trading of its shares.
Transaction Details for the Second Half of 2025
During the period from July 1 to December 31, 2025, the provider executed 2,481 purchase transactions and 2,724 sale transactions, the company reports. The traded volumes amounted to 384,725 shares for a total of 44,989,151.30 euros in purchases. On the sales side, 392,691 shares were sold for a total amount of 45,795,172 euros. These figures indicate the sustained activity of the liquidity contract in the second half of 2025, with a slightly higher number of sale transactions compared to purchases. This arrangement allows Ipsen to maintain an active market for its shares in compliance with current stock market regulations.
About Ipsen
Ipsen is an international biopharmaceutical group specializing in the development of innovative drugs in three main therapeutic areas: oncology, rare diseases, and neuroscience, according to the company's presentation. The group has development hubs in the United States, France, and the United Kingdom, and relies on nearly 100 years of experience in the pharmaceutical sector. Its teams are present in more than 40 countries and the company markets its drugs in over 100 countries worldwide through international partnerships. Ipsen's shares are listed on Euronext Paris and are also part of a Level I American Depositary Receipt program in the United States.
